ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1802

Behcet’s Disease in the Southwestern United States

Maheswari Muruganandam1 and Noelle Rolle2, 1Rheumatology, University of New Mexico Health Sciences Center, ALBUQUERQUE, NM, 2Rheumatology, University Of New Mexico Health Sciences Center, ALBUQUERQUE, NM

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, Hispanic patients, ulcers and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Behcet’s disease (BD) in the US is estimated to have a prevalence of 5.2-6.6 per 100,000 populations which is similar to that of European countries but lower than that reported along the Silk Road and in Turkey (400 per 100,000). We now report the demographic and clinical characteristics of BD in understudied populations in Southwest US.

Methods: Under IRB approval, we identified BD patients actively seen during 2014 to 2017 and determined the demographic and clinical characteristics of BD. BD was defined using the International Behcet’s Study Group criteria. Incomplete BD patients were excluded.

Results: 63 patients (82.5% female, 17.5% male, female: male ratio:  4.7:1) were identified who fulfilled definite BD criteria in a service population of 710,000 individuals, resulting in an estimated prevalence of 8.9 per 100,000 which is higher than reported previously in the US.  84.1% (53/63) were incorrectly diagnosed with other primary diagnoses like inflammatory arthritis (15.9%), primary fibromyalgia (7.9%), other forms of vasculitis (7.9%), or systemic lupus erythematous (7.9%) prior to BD diagnosis. Most common BD manifestations were oral ulcers (100%) (Figure 1), genital ulcers (61.9%) (Figure 2), acneiform lesions (69.8%), papulopustular lesions (52.4%) (Figure 2), pseudo folliculitis (42.9%), inflammatory arthritis (41.3%), anterior uveitis (23.8%), posterior uveitis (15.9%), pathergy (15.9%), deep vein thrombosis (14.3%), non-ocular vasculitis (11.1%), erythema nodosum (7.9%), arterial thrombosis (6.3%), and retinal vasculitis (1.6%).  50.8% of BD had concomitant fibromyalgia.  BD was distributed ethnically as follows: 49.2% Spanish-American (SA), 31.7% Non-Spanish European-American (EA), 14.3% Native American (NA), and only 1.7% Silk Road. HLA-B51 was present in 70.5% percent of the total BD population and demographically segregated as to HLA-B51 more commonly in NA (89.0%, p=0.02) and SA (74.2%, p=0.02) compared to EA (42.1%).

Conclusion: BD is more common in Southwestern US than anticipated from prior US-based studies. BD occurs amongst all local ethnic groups including EA, SA, and NA.  84.1% of BD patient have been incorrectly diagnosed with some other disease prior to the BD diagnosis, and 50.8% have concomitant fibromyalgia, complicating the diagnosis.  The prevalence of HLA-B51 in BD amongst SA and NA is high (74-89%) and greater than in EA (42%).  This is one of the first reports of the characteristics of BD in Southwest US, and specifically in SA and NA populations, and provides the basis for further future study.

Figure 1.  Oral ulceration

Figure 2. Genital ulceration and Papulopustular Lesions

 


Disclosure: M. Muruganandam, None; N. Rolle, None.

To cite this abstract in AMA style:

Muruganandam M, Rolle N. Behcet’s Disease in the Southwestern United States [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/behcets-disease-in-the-southwestern-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/behcets-disease-in-the-southwestern-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology